Soriot talks up an independent AstraZeneca
This article was originally published in Scrip
CEO Pascal Soriot used AstraZeneca's R&D day to talk up the company's rosy prospects as an independent company. Although the likelihood of a renewed takeover bid by Pfizer looks to be waning, he is taking no chances, and at the meeting with investors R&D leaders from across the company took to the podium to explain how bright the company's future looks.
You may also be interested in...
See how much the CEOs and R&D heads of the world’s biggest pharma companies get paid, and how those companies are performing.
Merck & Co is gradually catching up with Roche in PD-1/L1 first-line triple-negative breast cancer treatment, but its presentation at ASCO on Keynote-355 includes mixed PFS results. Overall survival data will be key to Keytruda’s competitiveness.
INFOGRAPHIC: A snapshot of the compensation packages granted to the chiefs of the world’s biggest pharma companies, along with key performance stats for the businesses they lead.